A novel low-molecular-weight compound enhances ectopic bone formation and fracture repair

Journal of Bone and Joint Surgery

Volumn 95, Issue 5, 2013, Pages 454-461

  Wong, Eugene ^a   Sangadala, Sreedhara ^b   Boden, Scott D ^c   Yoshioka, Katsuhito ^d   Hutton, William C ^c   Oliver, Colleen ^b   Titus, Louisa ^b  

^a Alfred Health   (Australia)

^b ATLANTA VA MEDICAL CENTER   (United States)

^c Emory Spine Center   (United States)

^d KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 VINYL 4,6 DIAMINO 1,3,5 TRIAZINE; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SVAK 12; TRIAZINE DERIVATIVE; UNCLASSIFIED DRUG; 2-VINYL-4,6-DIAMINO-1,3,5-TRIAZINE; BONE MORPHOGENETIC PROTEIN 2; ENZYME INHIBITOR; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE; VINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE RADIOGRAPHY; CALLUS; CELL DIFFERENTIATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG SAFETY; FEMUR FRACTURE; FRACTURE HEALING; IN VITRO STUDY; MALE; MECHANICAL TORSION; NONHUMAN; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; RAT; ANIMAL; BIOMECHANICS; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; EVALUATION; FRACTURE; GROWTH, DEVELOPMENT AND AGING; INTRALESIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RADIOGRAPHY; RANDOMIZATION; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; BIOMECHANICS; BONE MORPHOGENETIC PROTEIN 2; BONY CALLUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMORAL FRACTURES; FRACTURE HEALING; FRACTURES, CLOSED; INJECTIONS, INTRALESIONAL; MALE; MODELS, ANIMAL; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; TRANSFORMING GROWTH FACTOR BETA; TREATMENT OUTCOME; TRIAZINES; UBIQUITIN-PROTEIN LIGASES; VINYL COMPOUNDS;

MLCS; MLOWN;

EID: 84876433078     PISSN: 00219355     EISSN: 15351386     Source Type: Journal    
DOI: 10.2106/JBJS.L.00275     Document Type: Article

References (24)

1. Kato S, Sangadala S, Tomita K, Titus L, Boden SD. A synthetic compound that potentiates bone morphogenetic protein-2-induced transdifferentiation of myoblasts into the osteoblastic phenotype. Mol Cell Biochem. 2011 Mar;349(1-2): 97-106. Epub 2010 Nov 26.
2. Okada M, Sangadala S, Liu Y, Yoshida M, Reddy BV, Titus L, Boden SD. Development and optimization of a cell-based assay for the selection of synthetic compounds that potentiate bone morphogenetic protein-2 activity. Cell Biochem Funct. 2009 Dec;27(8): 526-34.
3. Hall J, Sorensen RG, Wozney JM, Wikesjö UM. Bone formation at rhBMP-2-coated titaniumimplants in the rat ectopicmodel. J Clin Periodontol. 2007 May;34(5): 444-51.
4. Bonnarens F, Einhorn TA. Production of a standard closed fracture in laboratory animal bone. J Orthop Res. 1984;2(1): 97-101.
5. Boden SD. Bone growth enhancing substances for spinal fusion. In: Garfin SR, Vaccaro AR, editors. Orthopaedic knowledge update. Spine. Rosemont: American Academy of Orthopaedic Surgeons; 1997. p 63-70.
6. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G,Mathevon H,McCoy G, Marsh D,Miller R,Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, RennieW, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Rüter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T; BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study Group. Recombinant human bone morphogenetic protein- 2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am. 2002 Dec;84-A(12): 2123-34.
7. Yamaguchi A, Komori T, Suda T. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev. 2000 Aug;21(4): 393-411.
8. Li G, Corsi-Payne K, Zheng B, Usas A, Peng H, Huard J. The dose of growth factors influences the synergistic effect of vascular endothelial growth factor on bone morphogenetic protein 4-induced ectopic bone formation. Tissue Eng Part A. 2009 Aug;15(8): 2123-33.
9. Bostrom MP, Lane JM, Berberian WS, Missri AA, Tomin E, Weiland A, Doty SB, Glaser D, Rosen VM. Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing. J Orthop Res. 1995 May;13(3): 357-67.
10. Einhorn TA, Majeska RJ, Mohaideen A, Kagel EM, Bouxsein ML, Turek TJ, Wozney JM. A single percutaneous injection of recombinant human bonemorphogenetic protein- 2 accelerates fracture repair. J Bone Joint Surg Am. 2003 Aug;85-A(8): 1425-35.
11. Ketenjian AY, Jafri AM, Arsenis C. Studies on the mechanism of callus cartilage differentiation and calcification during fracture healing. Orthop Clin North Am. 1978 Jan;9(1): 43-65.
12. Boden SD. Bioactive factors for bone tissue engineering. Clin Orthop Relat Res. 1999 Oct;(367 Suppl): S84-94.
13. Sakai R, Miwa K, Eto Y. Local administration of activin promotes fracture healing in the rat fibula fracture model. Bone. 1999 Aug;25(2): 191-6.
14. Nakamura Y, Tensho K, Nakaya H, Nawata M, Okabe T, Wakitani S. Low dose fibroblast growth factor-2 (FGF-2) enhances bone morphogenetic protein-2 (BMP-2)-induced ectopic bone formation in mice. Bone. 2005 Mar;36(3): 399-407.
15. Siu RK, Lu SS, Li W, Whang J, McNeill G, Zhang X, Wu BM, Turner AS, Seim HB 3rd, Hoang P, Wang JC, Gertzman AA, Ting K, Soo C. Nell-1 protein promotes bone formation in a sheep spinal fusion model. Tissue Eng Part A. 2011 Apr;17(7-8): 1123-35. Epub 2011 Feb 8.
16. Nash TJ, Howlett CR, Martin C, Steele J, Johnson KA, Hicklin DJ. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994 Mar-Apr;15(2): 203-8.
17. Higashino K, Viggeswarapu M, Bargouti M, Liu H, Titus L, Boden SD. Stromal cell-derived factor-1 potentiates bone morphogenetic protein-2 induced bone formation. Tissue Eng Part A. 2011 Feb;17(3-4): 523-30. Epub 2010 Nov 2.
18. Miguel BS, Ghayor C, Ehrbar M, Jung RE, Zwahlen RA, Hortschansky P, Schmoekel HG, Weber FE. N-methyl pyrrolidone as a potent bone morphogenetic protein enhancer for bone tissue regeneration. Tissue Eng Part A. 2009 Oct; 15(10): 2955-63.
19. Behnam K, Phillips ML, Silva JD, Brochmann EJ, Duarte ME, Murray SS. BMP binding peptide: a BMP-2 enhancing factor deduced from the sequence of native bovine bone morphogenetic protein/non-collagenous protein. J Orthop Res. 2005 Jan;23(1): 175-80.
20. Boden SD. Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng. 2000 Aug;6(4): 383-99.
21. Pauly S, Luttosch F, Morawski M, Haas NP, Schmidmaier G, Wildemann B. Simvastatin locally applied from a biodegradable coating of osteosynthetic implants improves fracture healing comparable to BMP-2 application. Bone. 2009 Sep; 45(3): 505-11. Epub 2009 May 21.
22. Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem. 2004 Mar 26;279(13): 12854-9. Epub 2003 Dec 29.
23. Sangadala S, Boden SD, Viggeswarapu M, Liu Y, Titus L. LIM mineralization protein-1 potentiates bone morphogenetic protein responsiveness via a novel interaction with Smurf1 resulting in decreased ubiquitination of Smads. J Biol Chem. 2006 Jun 23;281(25): 17212-9. Epub 2006 Apr 11.
24. Sangadala S, Boden SD, Metpally RP, Reddy BV. Modeling and analysis of molecularinteraction between Smurf1-WW2 domain and various isoforms of LIM mineralization protein. Proteins. 2007 Aug 15;68(3): 690-701.